Skip to search formSkip to main contentSkip to account menu

tipranavir

Known as: 3'-((1R)-1-((6R)-5,6-dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2h-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide, tipranavir [Chemical/Ingredient] 
A non-peptidomimetic agent that inhibits both wild type and drug resistant forms of human immunodeficiency virus (HIV) protease.
National Institutes of Health

Related topics

Related topics

7 relations

Broader (3)

Anti-HIV AgentsPyridinesPyrones
HIV Protease Inhibitors [MoA]Tipranavir:MCnc:Pt:Ser:QnTipranavir:Susc:Pt:Isolate:OrdQn

Narrower (1)

PNU 140690

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Efficacy of new antiretroviral drugs in treatment‐experienced HIV‐infected patients: a systematic review and meta‐analysis of recent randomized controlled trials
We performed a systematic review and meta‐analysis of randomized controlled trials (RCTs) to assess the overall efficacy of new… 
2011
2011
Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
2010
2010
HIV-1 non-B subtypes: High transmitted NNRTI-resistance in Spain and impaired genotypic resistance interpretation due to variability.
2009
2009
Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass…
2007
2007
Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals.
Concomitant HIV and hepatitis C virus (HCV) is a common yet complex coinfection. The present document is a practical guide for… 
Highly Cited
2006
Highly Cited
2006
Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.
BACKGROUND Current protease inhibitors (PIs) are designed against HIV-1, and information on their performance against HIV-2… 
2006
2006
Unexpected drug–drug interaction between tipranavir/ritonavir and enfuvirtide
Fifty-five patients placed on tipranavir/ritonavir 500/200 mg twice a day (27 with enfuvirtide and 28 without) underwent… 
Highly Cited
2006
Highly Cited
2006
Natural Polymorphisms in the Human Immunodeficiency Virus Type 2 Protease Can Accelerate Time to Development of Resistance to Protease Inhibitors
ABSTRACT Human immunodeficiency virus type 2 (HIV-2) contains numerous natural polymorphisms in its protease (PR) gene that are… 
Highly Cited
2004
Highly Cited
2004
Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers
Abstract Purpose: To characterize the steady-state pharmacokinetic combination of the nonpeptidic protease inhibitor tipranavir… 
2004
2004
A 14-Day Dose-Response Study of the Efficacy, Safety, and Pharmacokinetics of the Nonpeptidic Protease Inhibitor Tipranavir in Treatment-Naive HIV-1–Infected Patients
Abstract:Tipranavir (TPV), a novel nonpeptidic protease inhibitor (NPPI), was administered to treatment-naive HIV-1–infected… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)